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Telomerase is present in human cancer cells but
absent in most somatic tissues. The messenger
RNA of human telomerase (hTERT) is alternatively
spliced into mostly nonfunctional products. We
sought to understand splicing so that we could
decrease functional splice isoforms to reduce telo-
merase activity in order to complement direct
enzyme inhibition. Unexpectedly,minigenes contain-
ing hTERT exons 5–10 flanked by 150–300 bp intronic
sequences did not produce alternative splicing.
A 1.1 kb region of 38 bp repeats 2 kb from the
exon 6/intron junction restored the exclusion of
exons 7 and 8. An element within intron 8, also >1 kb
from intron/exon junctions, modulated this effect.
Transducing an oligonucleotide complementary
to this second element increased nonfunctional
hTERT messenger RNA from endogenous telome-
rase. These results demonstrate the potential of
manipulating hTERT splicing for both chemotherapy
and regenerative medicine and provide specific
sequences deep within introns that regulate alterna-
tive splicing in mammalian cells by mechanisms
other than the introduction of cryptic splice sites.INTRODUCTION
Chromosome ends are protected by repetitive noncoding
TTAGGG sequences known as telomeres. Initially, each human
chromosome is capped by 15–20 kb of telomere repeats. DNA
sequences are lost with every cell division due to incomplete
replication of the DNA lagging strand (the end-replication prob-
lem) and end-processing events (Levy et al., 1992; Olovnikov,
1973; Watson, 1972). Telomeres shorten progressively until a
critically shortened length is reached that triggers cellular senes-
cence (Harley, 1991; Wright et al., 1996a). The limited prolifera-
tive capacity of replicative aging is thought to provide an initial
barrier that prevents premalignant cells from progressing to ma-
lignant cancer cells (Harley, 1991).
To overcome this block to unlimited growth, cancer cells
almost universally upregulate/reactivate telomerase. Telomerase
is a ribonucleoprotein in which the reverse-transcriptase activity1028 Cell Reports 3, 1028–1035, April 25, 2013 ª2013 The Authorsof the protein component (hTERT) catalyzes telomere elonga-
tion using the RNA template component (hTR) (Greider, 1990).
Telomerase is normally expressed inproliferative stemandgerm-
line cells but is repressed during development in most human
tissues (Wright et al., 1996b). Re-expression of telomerase
prevents the progressive shortening of telomeres and cellular
senescence and is almost universally themechanism that cancer
cells use to escape replicative senescence (Shay and Bacchetti,
1997). Indeed, expression of hTERT in telomerase-negative
normal diploid cells results in cell immortalization (Bodnar et al.,
1998) without progressing cells to cancer (Morales et al., 1999).
Telomerase activity has been detected in the vast majority
(90%) of cancer cells (Kim et al., 1994; Shay and Bacchetti,
1997). A recombination-based mechanism named alternative
lengthening of telomeres (ALT) is used to maintain telomeres in
some telomerase-negative tumors (Bryan et al., 1997).
Significant efforts have been expended to develop telomerase
as a target for treating cancer. Imetelstat (GRN163L) is a modi-
fied oligonucleotide that binds to the template region of hTR,
acting as an active-site inhibitor (Marian et al., 2010). Imetelstat
has shown successes in inhibiting telomerase activity in xeno-
graft models (Joseph et al., 2010) and is currently in limited clin-
ical trials. However, it remains unclear if Imetelstat as a single
agent will achieve sufficient sustained inhibition in patients to
drive cancer cells into crisis. Other types of telomerase inhibitors
developed thus far (such as antisense oligonucleotides and ribo-
zymes) with inhibitory effects on telomerase in model systems
have not successfully progressed to clinical trials due to toxicity,
low specificity, and/or inefficient delivery (Chen et al., 2009; Kole
et al., 2012). Development of alternative telomerase inhibitors,
used in combination or following standard cancer therapy, may
enhance the potential of telomerase as a therapeutic target.
An in-depth understanding of the regulation of telomerase in
normal development and its aberrant expression in cancer cells
may provide additional targets for the development of novel ther-
apeutics. Increasing evidence suggests that both transcriptional
and posttranscriptional processes are involved in regulating
human telomerase (Daniel et al., 2012). In this study, alternative
splicing of hTERT was examined as a posttranscriptional
regulatory step that could potentially provide a new approach
for inhibiting telomerase.
The telomerase transcript containing 16 exons can be spliced
intomultiple isoforms (Kilian et al., 1997). During kidney develop-
ment, telomerase activity disappears before transcripts because
of a dramatic shift in splicing patterns (Ulaner et al., 2001). The
major isoforms studied in cultured cancer cells involve exons
6–9 that encode part of the reverse-transcriptase domain. Of
these, only the ‘‘full-length’’ transcript (that includes all four intact
exons) can be translated into an active enzyme. The minus alpha
isoform is a dominant-negative inhibitor of telomerase that lacks
a portion of exon 6 (Yi et al., 2000). The major splice form (minus
beta) skips exons 7 and 8 and contains a premature stop codon
that is subject to nonsense-mediated decay. The current
best estimate for the number of catalytically active telomerase
molecules per cell is 50–100 (Cohen et al., 2007), produced
from 20 messenger RNA (mRNA) molecules per cell (Yi et al.,
2001). Only a small fraction of the hTERT transcripts are spliced
into the full-length form that can generate the catalytically active
protein. A working hypothesis to explain these results is that the
transcriptional machinery is unable to reduce transcription to a
level that produces only a few mRNA molecules per cell, so
that 20 mRNA molecules per cell might represent the lower
limit of transcriptional regulation. The cell then disposes of this
excess transcription by alternatively splicing most into nonfunc-
tional forms in order to produce the very low levels of protein
needed to maintain telomere length in cancer cells. Almost
nothing is currently known about the regulation of very low abun-
dant proteins such as telomerase, even though this gene was
identified over 15 years ago.
To address this deficiency, we constructed an hTERT mini-
gene containing 150–300 intronic sequences flanking hTERT
exons 5–10. Surprisingly, it failed to produce significant amounts
of alternatively spliced products. It was previously known that
large, long-lived mammals regulated telomerase differently
from many small, short-lived mammals (Gomes et al., 2011).
We then identified several intronic sequences in the telomerase
gene that were conserved in primates but not in other mamma-
lian species. These included a 1,100 bp VNTR (variable number
tandem repeats) composed of 38 bp repeats in intron 6 and a
260 bp sequence that was present as a direct repeat in both
introns 6 and 8 (flanking the exons removed in themajor nonfunc-
tional isoform that eliminates exons 7 and 8). Each of these ele-
ments was a kilobase or more from any splice junction. Including
these elements in theminigene reconstituted alternative splicing.
Exon-skipping oligonucleotides complementary to a region at
the beginning of the 260 nt direct repeat decreased the amount
of functional splice forms transcribed from the endogenous
gene, providing validation of this mechanism involved in splicing.
Understanding the detailed mechanism(s) by which these regu-
latory sequences function to direct hTERT splicing choices
may identify new telomerase inhibitor targets that could be
used in combination with standard cancer chemotherapy and/
or other telomerase inhibitors to reduce cancer recurrences
(e.g., durable responses) as well as interventions to increase
telomerase activity in stem cells for regenerative medicine.
RESULTS
Telomerase Splicing Is Differentially Regulated in
Different Cancer Cell Lines
The 42 kb telomerase (hTERT) gene on chromosome 5 contains
16 exons. Besides the full-length transcript with all 16 exons,
none of the identified alternative spliced forms has reverse tran-
scriptase activity (Saebøe-Larssen et al., 2006; Yi et al., 2000).CThe alternatively spliced isoforms within the reverse-transcrip-
tase domain include minus alpha, minus beta, or both (minus
alpha beta) (Figure 1A). The inclusion of all five exons (5-6-7-8-
9) is designated 5–9 (this would encode active telomerase in
the absence of additional changes outside this region). The
minus alpha splicing isoform uses an alternative 30 splice
acceptor site 36 bp into exon 6, resulting in an in-frame transcript
that is translated into a dominant-negative protein without
reverse-transcriptase activity (Yi et al., 2000). The minus beta
splicing isoform skips exons 7 and 8, creating a frameshift and
encountering a premature stop codon in exon 10. It is the major
splicing isoform of hTERT transcripts in cancer cells, and its
steady-state level is at least five times less than its rate of
production since it is subject to degradation by nonsense-
mediated decay.
Telomerase alternative splicing was examined in a variety of
cancer cell lines (Figure 1B). The ratio of transcripts spliced
into each of the isoforms varied slightly between each line.
Minigene Requires Conserved Distant Intronic
Sequences to Recapitulate Normal Splicing
We constructed a minigene containing exons 5 to 10 and 150–
300 flanking nucleotides (Figure 1C). The regions immediately
downstream of exons 6 and 8 were unusually GU rich, so we
included 325–362 bp from these regions. This minigene contain-
ing 3,669 bp was inserted into the pcDNA/FRT vector and stably
transfected into a HeLa clone selected for a single FRT site intro-
duced by Invitrogen’s Flp-In system to reduce the variability
arising from random genomic incorporation. Alternative splicing
was determined using a minigene-specific forward primer. The
basic minigene only produced 5–9 and minus alpha splicing
and therefore was unable to recapitulate the endogenous telo-
merase splicing pattern (Figure 1D).
The human telomerase gene contains a block of 26 short
repeats with a strong 38 nt consensus sequence 1,900 nt
downstream of exon 6 (Figures 1E and 1F). This block of repeats
in intron 6 (B6, block 6) is immediately followed by a 256 nt direct
repeat in intron 6 (DR6), which has 85% sequence similarity with
a 258 nt direct repeat in intron 8 (DR8). DR8 is 1,500 nt down-
stream of exon 7. These elements are highly conserved among
old world primates (Figure S1), suggesting a functional role in
regulation. A separate and unrelated second block of repeats
1,270 nt downstream from DR6 is also conserved among pri-
mates, but the number of repeats varies greatly and therefore
was not included in the minigene in this initial study. The endog-
enous hTERT splicing isoforms were restored when B6, DR6,
and DR8 were incorporated into the minigene (‘‘full’’ minigene)
(Figures 1G and 1H, construct c2).
Block 6 Is Necessary for Minus Beta Splicing
The addition of just the direct repeats in intron 6 and 8 to the
basic minigene failed to produce significant amounts of minus
beta splicing (Figure 2A, construct c3). In contrast, the addition
of B6 alone (Figure 2A, construct c4) was sufficient to enhance
exon 7 and 8 skipping to produce a high proportion of minus
beta splicing. The combination of B6 and the direct repeat in
intron 6 produced exclusively minus beta splicing (Figure 2A,
construct c5), while the combination of B6 and the direct repeatell Reports 3, 1028–1035, April 25, 2013 ª2013 The Authors 1029
Figure 1. Identification of Long-Range Interactions Required to Produce Minus Beta Splicing
(A) Diagram illustrating the exons and introns of human telomerase (not to scale). Functional telomerase is made from the full-length transcript containing all 16
exons. The splicing isoforms within the reverse-transcriptase domain (minus alpha and minus beta) are indicated. The minus beta splicing isoform creates a
frameshift and a premature stop codon as indicated in exon 10. The gene-specific primer used tomake the complementary DNA (cDNA) lies within exon 9 (arrow).
PCR primers for endogenous splicing used a forward primer in exon 5 and a reverse cy5-labeled primer in exon 9 (arrows).
(B) PCR analysis of endogenous hTERT splicing showing a similar splicing pattern among cancer cell lines. The 5–9 splicing includes the functional full-length
transcript (other potential isoforms might contain changes outside this assayed region). Minus beta is the dominant isoform in all cell lines, but variations in the
distribution of each splice variant are cell-line specific.
(C) Diagram of human telomerase from exon 5 to exon 10, with exon sizes indicated above and intron sizes below (top) and the sequences included in the
telomerase basic minigene (construct 1 [c1], bottom). All exonic sequences from exon 5 to exon 10 are included in the minigene, whereas only flanking intronic
sequences are included. The values before and after the forward slash (/) indicate the 50 intronic and 30 intronic sequences adjacent to the exons used. The
minigene was inserted into pcDNA5/FRT driven by a CMV promoter. The gene-specific primer used to make cDNA and the reverse cy5-labeled primer for PCR is
the same as the primers used for endogenous TERT analysis. However, the forward PCR primer lies within the pcDNA5/FRT vector just before exon 5, making it
minigene specific.
(D) Splicing analysis of the basic minigene illustrated in (C) yielded only 5–9 and minus alpha products.
(E) Self-blast of human telomerase showing a block of repeats in intron 6 (block 6), a direct repeat in intron 6 (DR6), and a direct repeat in intron 8 (DR8).
(F) Sequence logo created by WebLogo (Parra et al., 2012) showing the strong 38 nt consensus sequence of the 26 repeats in block 6.
(G) Diagram of the full minigene (c2) including block 6 (B6), the direct repeat in intron 6 (DR6), and the direct repeat in intron 8 (DR8).
(H) Splicing analysis of the full minigene illustrated in (E) showedminus beta formation. Data are fromHeLa FRT clone 8 cells stably transfectedwith theminigenes.
See also Figure S1.in intron 8 shifted splicing toward greater inclusion of all the
exons (Figure 2A, construct c6). Thus, while the direct repeats
by themselves are not sufficient to produce the skipping of exons
7 and 8 (minus beta, construct c3), theymodulate the ability of B6
to shift splicing toward nonfunctional forms.1030 Cell Reports 3, 1028–1035, April 25, 2013 ª2013 The AuthorsThe Effects of the Direct Repeats on the Alternative
Splicing of Telomerase Is Position Dependent
Switching the positions of direct repeats 6 and 8 did not change
the splicing of the hTERT minigene (Figure 2B, construct c2
versus construct c7). Similarly, there was little difference when
Figure 2. Effects of Distal Elements B6, DR6, and DR8 on Alternative Splicing
(A) DR6 and DR8 (construct c3) do not generate significant exon skipping in the absence of B6 (construct c2). B6 without DR6 and DR8 is sufficient to produce
minus beta splicing (c5). Adding DR6 to B6 (c5) modifies its activity and virtually eliminates all 5–9 products that include all of the exons. Adding only DR8 to B6 (c6)
shifts splicing in the opposite direction and increases the amount of 5–9 splicing.
(B) Switching the position of DR6 and DR8 in the presence of B6 does not change the ratio of 5–9 to minus beta splicing (c7 versus c2).
(C) DR6 andDR8 produce similar effects when positioned as the direct repeat only in intron 6 (construct 5 versus construct 8) or only in intron 8 (construct 6 versus
construct 9). It is thus the position of the direct repeats rather than their sequence difference that influences splice choice. All constructs were analyzed in HeLa
FRT clone 8 cells.the direct repeats were substituted for each other. Replacing
DR6 with DR8 (Figure 2C, construct c5 versus construct c8) or
replacing DR8 with DR6 (Figure 2C, construct c6 versus
construct c9) did not significantly change the splicing pattern.
This suggests that it is the intronic location rather than the
sequence differences between DR6 and DR8 (Figure 3A) that
influences their effect on splicing.
An Antisense Oligonucleotide Supports the Effect of the
Direct Repeat in Intron 8 Established by the Minigene
Model
Because the direct repeat in intron 8 suppressed the minus-
beta-promoting effects of the direct repeat in intron 6 in the mini-
gene, we tested whether interfering with its structure might
change the splicing of the endogenous TERT gene. Figure 3B
demonstrates that an antisense oligonucleotide (DR8+19, aC20-mer beginning at nucleotide 19 of the DR8 sequence)
directed against DR8 shifted the splicing of endogenous hTERT
to mostly minus beta splicing. This confirms that the behavior of
the minigene is recapitulating important aspects of endogenous
regulation.
AMinimumNumber of ConsensusRepeats AreRequired
for the Minus Beta Splicing Effects of Block 6
Theminimumnumber of repeats present in the primate genomes
examined was nine repeats (bonobo; Figure S1). The B6
sequence in the full minigene (c2) was replaced with varying
number of the consensus repeat sequence in order to determine
the minimum number required to increase minus beta splicing.
With one or five repeats, the minigenes did not induce minus
beta splicing. However, 11 or more repeats did restore the effect
(Figure 4A).ell Reports 3, 1028–1035, April 25, 2013 ª2013 The Authors 1031
Figure 3. DR8-Directed Oligonucleotides
Alter theSplicingofEndogenousTelomerase
(A) The direct repeats DR6 and DR8 are 85%
identical and are members of the J1 family of Alu
repeats. The sequence of the 20 bp 2-O-methyl
oligonucleotide containing 50% thiophosphate
linkages complementary to the region starting at
nucleotide 19 is boxed.
(B) Introduction of the oligonucleotide DR8+19
dramatically shifts splicing of the endogenous
telomerase mRNA toward the production of
the nonfunctional minus beta isoform. Cells
were treated with 100 nM DR8+19 oligonucleo-
tide or vehicle control. Right side shows the
quantification.Single Mutations Disrupt Block 6 Function
When various numbers of 38 nt repeats were analyzed using the
Mfold web server (Zuker, 2003), the majority of the putative
structures were dominated by the staggered overlap shown in
Figure 4B, in which one repeat interacted with two adjacent
half-repeats. We introduced two different single mutations into
the 38 bp repeat, G28/A (predicted to be found in the top
loop of the self-complementary repeat structure) and G15/A
(predicted to be located in two different double-stranded re-
gions, disrupting neither of them). These mutations completely
or almost completely abolished the ability of 13 repeats to pro-
duce minus beta splicing (Figure 4C).
DISCUSSION
We used a minigene system to identify the pre-mRNA
sequence elements required for in vivo hTERT (human telome-
rase) splicing regulation. In contrast to most alternative splicing
events that have been studied, the splicing of hTERT is regu-
lated by long-range interactions rather than by the intronic/
exonic elements adjacent to the splice sites. We identified
three elements that were highly conserved among primates
that were embedded in introns 6 and 8. These elements sur-
round the alternative exons 7 and 8, where the elimination of
these exons results in the major nonfunctional minus beta telo-
merase isoform. Only when these elements were included in
the telomerase minigene did we observe the various splicing
isoforms seen with the endogenous gene. Chromatin immuno-1032 Cell Reports 3, 1028–1035, April 25, 2013 ª2013 The Authorsprecipitation sequencing data indicate
many potential splicing factor binding
sites at long distances from intron/exon
junctions (Yeo et al., 2009), but few
specific examples of regulation-at-a-
distance have been previously reported.
These elements in the telomerase gene
represent examples in mammals of spe-
cific distant sequences that influence
splice choice by a mechanism other
than introducing cryptic splice sites
(Dominski and Kole, 1993; Friedman
et al., 1999; Parra et al., 2012; Pros
et al., 2009; Salem et al., 2012).The block of repeats in intron 6 is necessary for the enhance-
ment ofminus beta splicing of telomerase, and aminimal number
of repeats is required for its function. The number of B6 repeats
varies greatly from 18–38 repeats among individuals (Leem et al.,
2002). Yet, the mechanism of how B6 repeats influence hTERT
splicing remains unknown. The importance of repeats can be
seen in the alternative splicing of the TAU gene. Intronic muta-
tions in TAU destabilize a stem-loop structure, thus increasing
inclusion of exon 10, and this correlates with frontotemporal
dementia and Parkinson disease (Varani et al., 1999). Another
example is seen in myotonic dystrophy type 1 (DM1), where an
expansion of (CUG)n repeats in DM protein kinase (DMPK)
sequesters Mbnl1 and increases the levels of CUGBP1, leading
to the aberrant splicing of genes governed by these splicing
factors (Mulders et al., 2009). The implication of altered repeats
resulting in diseases suggests that a possible link between the
B6 repeats of telomerase and cancer development warrants
further investigation.
The direct repeats in introns 6 and 8 have 85% sequence
similarity, but their effects on telomerase splicing are very
different. When these elements were switched, the position of
the element rather than the nucleotide sequence governed its
effect on telomerase splicing. This suggests that the direct re-
peats may function by recruiting similar RNA binding proteins
based on their sequences and that the interactions of these bind-
ing proteins with other neighboring proteins may dictate the
splicing decision. This is similar to studies demonstrating that
the effects of SR and heterogeneous nuclear ribonucleoprotein
Figure 4. Length andMutational Analysis of
Block 6
(A) Left side shows splicing products of HeLa FRT
clone 8 cells stably transfected with minigenes
containing varying numbers of block 6 consensus
repeats. Right side shows the quantification. Less
than 11 repeats failed to produce significant
amounts of minus beta splicing.
(B) Secondary RNA folding structures predicted by
Mfold for B6 self-interactions for the consensus
sequence and two mutants. The structures
with the lowest free energies are shown. The
consensus 38 bp repeat can self-fold into a highly
structured staggered secondary structure. One
complete (black) and two half-consensus repeats
(red and blue) are highlighted. Neither mutant
G28/A normutant G15/A altered this structure,
and both self-folded similarly to the consensus
repeat. The mutated nucleotides are in red and
highlighted in yellow.
(C) Mutations that do not alter the secondary
structure of self-folding abolish minus beta
splicing.binding are highly dependent on their position with respect to
splice sites (Llorian et al., 2010; Yeo et al., 2009). The mecha-
nisms and factors involved in telomere maintenance throughout
evolution are extraordinarily diverse, indicating the lack of con-
straints to evolving multiple specific mechanisms for protecting
the ends of the chromosomes from degradation (Fajkus et al.,
2005; Nosek et al., 2006). Even amongmammals there is consid-
erable diversity in the size and use of telomeres (Gomes et al.,
2011). The conservation among higher primates, but not other
mammals, of the elements is consistent with the evolutionary di-
versity of known telomere maintenance mechanisms.
There are large numbers of different avenues for exploiting
these observations to develop therapeutic interventions. For
example, screening for small molecules or small interfering
RNAs that alter the splicing pattern is likely to be the best
long-term approach. There are many recently discovered
‘‘telomeropathies’’ due to mutations in telomerase or one of its
components (Garcia et al., 2007), and increasing evidence
suggests that telomere shortening in stem cells may contribute
to the failure to adequately maintain tissues in late life. There
may be many minor or previously uncharacterized spliceosome
factors that influence these long-range interactions in different
directions, where some factors would decrease full-length
functional telomerase and be important for the treatment of
cancer while others would increase functional telomerase and
provide therapeutics for regenerative medicine. Increasing our
understanding of the regulation of telomerase at the level of
splicing may provide additional pathways for manipulating the
function of this critical ribonucleoprotein enzyme that influences
human health at multiple levels.Cell Reports 3, 1028–103EXPERIMENTAL PROCEDURES
Cell Culture
HeLa cervical carcinoma, H1299 lung adenocarci-
noma, 293FT embryonic kidney, DLD-1 colon
carcinoma, RKO-1 colon carcinoma, HT29 colonadenocarcinoma, and HCT116 colorectal carcinoma cells were cultured at
37C in 5% CO2 in 4:1 Dulbecco’s modified Eagle’s medium:Medium 199
containing 10% calf serum (HyClone, Logan, UT).
Generation of Cells Containing an FRT Site
The Flp-In System (Invitrogen, Carlsbad, CA) was used to generate HeLa cells
with a stably integrated FRT site. FRT stably integrated clones were screened
for single insertion by Southern blotting and adequate expression by b-galac-
tosidase staining. The data from a single clone (HeLa clone 8) are shown in
Figures 2, 3, and 4. Additional clones with different FRT insertion sites were
used to confirm several of the results observed in HeLa clone 8.
Construction of Minigene Plasmids
Human telomerase sequences were inserted in the pcDNA5/FRT expression
vector (Invitrogen) using a variety of restriction sites. The sequence of the
minigene is available upon request.
RT-PCR and Splicing Analysis
RNA was extracted from stable minigene expressing HeLa cells using the
RNeasy Plus Mini Kit (QIAGEN, Valencia, CA). Complementary DNA was
made by combining 1 mg RNA, 1 ng telomerase-specific primer (50-CGCAAA
CAGCTTGTTCTCCATGTC-30), and hybridization buffer (1.5 M NaCl, 50 mM
Tris [pH 7.5], 10 mM EDTA). The mixture was heated to 90C. Temperature
was decreased by 1C every 20 s until 43C, and then Moloney murine
leukemia virus reverse transcriptase (Promega, Madison, WI) was added
with 1.253 reverse-transcriptase mix (1.25 mM dNTP, 12.5 mM dithiothreitol,
12.5 mM Tris [pH 8.0], 7.5 mM MgCl2). The reaction was incubated at 43
C
for 30 min and then heated to 94C for 5 min. To amplify minigene
specific telomerase splicing isoforms, the forward primer 50-CTGGCTAACTA
GAGAACCCACTGC-30 and the cy5-labeled reverse primer 50- AGGCTGCA
GAGCAGCGTGGAGAGG-30 were used with Taq polymerase PCR (Promega)
in RT-PCR buffer (0.5 M KCl, 0.1 M Tris [pH 8.3], 15 mM MgCl2, 0.01%
gelatin). The reaction was initially denatured at 94C for 3 min and then dena-
tured at 94C for 30 s, annealed at 61C for 30 s, and extended at 72C for
1 min for 30 cycles, with a final extension at 72C for 10 min. The PCR product5, April 25, 2013 ª2013 The Authors 1033
was resolved on a 5% denaturing polyacrylamide gel and visualized at
650 nm.
Annealing Oligonucleotides to Generate Consensus and Mutant
Block 6 Repeats
In separate reactions, equal molar ratios of the top and bottom strands of the
terminating ends containing restriction sites and the overlapping mutant re-
peats were annealed using 13 annealing buffer (10 mM Tris [pH 8.0], 50 mM
NaCl, 1 mM EDTA), heated to 95C for 5 min and then gradually cooled to
room temperature. The sequence and strategy are shown in Extended Exper-
imental Procedures. After purifying the annealed DNA using the QIAquick Gel
Extraction Kit (QIAGEN), the terminating endswere combinedwith the overlap-
ping consensus or mutant repeats at a 1:40:1 ratio. After ligating the mixture
overnight at room temperature using T4 DNA ligase (Fermentas, Canada), liga-
tion products were separated on a 1% agarose gel. Gel-purified size classes
were thendigestedwith restriction enzymes and ligated to theminigene vector.
Antisense Oligonucleotide
The 2-O-methyl oligonucleotide DR8+19 oligonucleotide (50-CGAUCUCAA
CUCACUGCAAC-30) containing 50% phosphothioate linkages was synthe-
sized by Integrated DNA Technologies. The oligonucleotide (100 nM)
was introduced into the cells by reverse transfection using Lipofectamine
RNAiMAX (Life Technologies Corporation, CA). Transfected cells were
collected after 48 hr and analyzed by RT-PCR.
For further details, please refer to Extended Experimental Procedures and
Figure S2.
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